ArticleBlood advances2017
Microenvironmental agonists generate
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 72 papers.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 114 citations in OpenAlex.
- Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.Blood advances · 2022Trial
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.Lancet (London, England) · 2018Trial
- Resistance pathways and next-generation treatments in chronic lymphocytic leukemia.Discover oncology · 2026Review
- CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.Leukemia · 2026Article
- Casein kinase 1δ/ε inhibition suppresses CLL proliferation through cell-intrinsic and microenvironmental mechanisms.HemaSphere · 2026Article
- Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.Leukemia · 2026Article
- FOXM1 induces therapy resistance and inhibits apoptosis in a variety of human cancers.Cell death & disease · 2026Review
- Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.Leukemia · 2025Review
- Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures.ACS pharmacology & translational science · 2025Review
- Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.American journal of hematology · 2025Review
- 20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-XFrontiers in pharmacology · 2025Article
- Advances and challenges in leukemia treatment: A focus on monoclonal antibodies and emerging therapies.Oncology research · 2025Review
- Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.Leukemia & lymphoma · 2024Article
- Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies.Cancers · 2024Review
- Enhancer-promoter hubs organize transcriptional networks promoting oncogenesis and drug resistance.Nature communications · 2024Article
- The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax.Hemato · 2024Article
- Bithionol eliminates acute myeloid leukaemia stem-like cells by suppressing NF-κB signalling and inducing oxidative stress, leading to apoptosis and ferroptosis.Cell death discovery · 2024Article
- Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status.Blood advances · 2024Article
- Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia.Cell death & disease · 2024Review
- BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism.Lymphatics · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 3 institutions in 1 country.
Kallesh D JayappaDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Craig A PortellDivision of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Vicki L GordonDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Brian J CapaldoDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, United States.
Stefan BekiranovDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, United States.
Mark J AxelrodGilead Sciences, 199 E. Blaine St., Seattle, WA, United States.
L Kyle BrettUtica Park Clinic, Medical Oncology, 1245 S Utica Ave Suite #100, Tulsa, OK, United States.
Julia D WulfkuhleCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, United States.
Rosa I GallagherCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, United States.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, United States.
Timothy P BenderDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Michael E WilliamsDivision of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Michael J WeberDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Carter Center · USGeorge Mason University · USUniversity of Virginia · US
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1MNCI NIH HHS P30 CA044579
Abstract
PubMed holds no abstract for this paper.
Indexed as
and Drug ResistanceCD40LChronic Lymphocytic Leukemia (CLL)CpG-ODNFollicular Lymphoma (FL)IbrutinibIL-10Mantle Cell Lymphoma (MCL)MicroenvironmentNF-κB signalingTLR9Venetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.